Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy
Sylvain Lamure(Centre National de la Recherche Scientifique), Guillaume Cartron(Hôpital Saint Eloi)
Cited by 36
Related Papers
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
|Blood|2019|136
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
|Nature Medicine|2024|127
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis
|The Lancet Haematology|2018|116